Genome Wide Association Studies in ECOG 2997 Trial

Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.

I. Flinn, D. Neuberg, M. Grever, et al.. (2007). Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Cited 384 times. https://doi.org/10.1200/JCO.2006.08.0762

Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997.

M. Grever, D. Lucas, G. Dewald, et al.. (2007). Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Cited 366 times. https://doi.org/10.1200/JCO.2006.08.3089

Framingham Heart Study 100K project: genome-wide associations for cardiovascular disease outcomes

M. Larson, Larry D. Atwood, Emelia J. Benjamin, et al.. (2007). BMC Medical Genetics. Cited 200 times. https://doi.org/10.1186/1471-2350-8-S1-S5

Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: long-term follow-up of US Intergroup Study E2997.

Mitchell R. Smith, D. Neuberg, I. Flinn, et al.. (2011). Blood. Cited 44 times. https://doi.org/10.1182/blood-2011-03-342485

Oral Contraceptive Hypertension and Thromboembolism

W. Kannel. (1979). International Journal of Gynecology & Obstetrics. Cited 22 times. https://doi.org/10.1002/j.1879-3479.1979.tb00951.x